May 23, 2017

Selexis SA and OSE Immunotherapeutics Sign Commercial License Agreement to Further Advance Development of OSE’s Interleukin Receptor 7 Antagonist

Read More
May 11, 2017

Selexis SA Opens New World-Class Laboratory Facility and Corporate Headquarters in Geneva, Switzerland

Read More
March 20, 2017

Selexis Announces Launch of Novel Cell Selection Platform Designed to Help Advance Difficult-to-Express Protein Therapeutics to the Clinic

Read More

Media Downloads